Table 1.
Results of receiver operating curve analysis on responders and non‐responders to dulaglutide treatment
| AUC | Sensitivity | Specificity | Cut‐off | P | |
|---|---|---|---|---|---|
| 111In‐Ex4 pancreatic value (MBq) | 1.00 | 1.00 | 1.00 | 0.04 | <0.01 |
| Bodyweight (g) | 0.66 | 0.71 | 0.80 | 40.40 | 0.25 |
| Age (weeks) | 0.53 | 0.86 | 0.20 | 29.00 | 0.79 |
| Mice glycohemoglobin (%) | 0.94 | 0.86 | 1.00 | 7.75 | 0.01 |
| Fasting glucose (mg/dL) | 0.77 | 0.71 | 0.80 | 118.00 | 0.09 |
| Non‐fasting glucose (mg/dL) | 0.86 | 0.86 | 0.80 | 357.000 | 0.01 |
| Fasting insulin/glucose (/104) | 0.66 | 0.57 | 0.80 | 4.99 | 0.26 |
| Non‐fasting insulin/glucose (/104) | 0.69 | 0.86 | 0.60 | 4.38 | 0.17 |
|
OGTT AUCglu (mg/dL × min) |
1.00 | 1.00 | 1.00 | 46102.50 | <0.01 |
| OGTT Δinsulin/Δglucose (0–30 min) (/104) | 1.00 | 1.00 | 1.00 | 2.62 | <0.01 |
AUCglu, area under curve of glucose during 2 h; AUROC, area under the receiver operating characteristic curve; GLP‐1RA, glucagon‐like peptide‐1 receptor agonists; Δinsulin/Δglucose (0–30 min), increment of serum insulin per blood glucose during 30 min; OGTT, oral glucose tolerance test.